stockrowBristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.02%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Bristol Myers Squibb Company (BMY) Return on equity
Bristol Myers Squibb Company's return on equity over the twelve months to 30 September 2026 was 44.0%, up 3.6 percentage points from fiscal 2025 (40.4%). Over the past ten years it has ranged from −39.0% (fiscal 2024) to 40.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 40.4% | 79.44 |
| FY2024 | −39.0% | (65.49) |
| FY2023 | 26.5% | 7.63 |
| FY2022 | 18.9% | (0.08) |
| FY2021 | 18.9% | 39.06 |
| FY2020 | −20.1% | (30.58) |
| FY2019 | 10.5% | (27.43) |
| FY2018 | 37.9% | 30.74 |
| FY2017 | 7.14% | (21.83) |
| FY2016 | 29.0% | 18.33 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 58.8% |
| BMY Bristol Myers Squibb Company | 44.0% |
| GSK GSK PLC Sponsored ADR compare | 25.5% |
| NVS Novartis AG compare | 24.4% |
| AZN AstraZeneca PLC compare | 22.6% |
| PFE Pfizer Inc. compare | 4.42% |
| SNY Sanofi compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −22.5% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement